GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyra Therapeutics Inc (NAS:LYRA) » Definitions » Gross Property, Plant and Equipment

Lyra Therapeutics (Lyra Therapeutics) Gross Property, Plant and Equipment : $49.41 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Lyra Therapeutics Gross Property, Plant and Equipment?

Lyra Therapeutics's quarterly gross PPE increased from Sep. 2023 ($6.80 Mil) to Dec. 2023 ($37.20 Mil) and increased from Dec. 2023 ($37.20 Mil) to Mar. 2024 ($49.41 Mil).

Lyra Therapeutics's annual gross PPE stayed the same from Dec. 2021 ($9.74 Mil) to Dec. 2022 ($8.64 Mil) but then increased from Dec. 2022 ($8.64 Mil) to Dec. 2023 ($37.20 Mil).


Lyra Therapeutics Gross Property, Plant and Equipment Historical Data

The historical data trend for Lyra Therapeutics's Gross Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyra Therapeutics Gross Property, Plant and Equipment Chart

Lyra Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Property, Plant and Equipment
Get a 7-Day Free Trial 6.25 7.34 9.74 8.64 37.20

Lyra Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.83 1.98 6.80 37.20 49.41

Lyra Therapeutics Gross Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the company. Fixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Lyra Therapeutics  (NAS:LYRA) Gross Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Lyra Therapeutics Gross Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Lyra Therapeutics's Gross Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyra Therapeutics (Lyra Therapeutics) Business Description

Industry
Traded in Other Exchanges
N/A
Address
480 Arsenal Way, Watertown, MA, USA, 02472
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Executives
Harlan Waksal director, officer: Executive Chair WAKSAL CONSULTING LLC, 7 NORTH WILLOW STREET, SUITE 6, MONTCLAIR NJ 07042
Nbvm Gp, Llc 10 percent owner 950 WINTER STREET, SUITE 4600, WALTHAM MA 02451
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Edward T Anderson director, 10 percent owner 950 WINTER ST SUITE 4600, WATHAM MA 02451
John E Bishop officer: Chief Technology Officer 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Richard Nieman officer: Chief Medical Officer C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
C Ann Merrifield director
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Jason Cavalier officer: Chief Financial Officer C/O LYRA THERAPEUTICS, INC., 1480 ARSENAL WAY, WATERTOWN MA 02472
Snyderman Nancy Lynn Md director 37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Pamela E. Nelson officer: Senior VP, Regulatory Affairs C/O LYRA THERAPEUTICS, INC., 1480 ARSENAL WAY, WATERTOWN MA 02472
Robert E. Richard officer: SVP of R&D C10 LYRA THERAPEUTICS, INC., 1480 ALSENAL WAY, WATERTOWN MA 02472
Soleus Private Equity Fund I, L.p. 10 percent owner C/O SOLEUS PRIVATE EQUITY GP I, LLC, 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Soleus Capital, Llc 10 percent owner 104 FIELD POINT ROAD, FLOOR 2, GREENWICH CT 06830
Polaris Venture Partners Special Founders' Fund V, L.p. 10 percent owner ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210